GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PepGen Inc (NAS:PEPG) » Definitions » Return-on-Tangible-Asset

PEPG (PepGen) Return-on-Tangible-Asset : -86.83% (As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is PepGen Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. PepGen's annualized Net Income for the quarter that ended in Mar. 2025 was $-120.81 Mil. PepGen's average total tangible assets for the quarter that ended in Mar. 2025 was $139.14 Mil. Therefore, PepGen's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -86.83%.

The historical rank and industry rank for PepGen's Return-on-Tangible-Asset or its related term are showing as below:

PEPG' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -61.23   Med: -38.28   Max: -17.75
Current: -60.17

During the past 5 years, PepGen's highest Return-on-Tangible-Asset was -17.75%. The lowest was -61.23%. And the median was -38.28%.

PEPG's Return-on-Tangible-Asset is ranked worse than
65.15% of 1498 companies
in the Biotechnology industry
Industry Median: -37.355 vs PEPG: -60.17

PepGen Return-on-Tangible-Asset Historical Data

The historical data trend for PepGen's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PepGen Return-on-Tangible-Asset Chart

PepGen Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
-17.75 -35.36 -38.28 -43.62 -61.23

PepGen Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.18 -56.60 -47.03 -55.41 -86.83

Competitive Comparison of PepGen's Return-on-Tangible-Asset

For the Biotechnology subindustry, PepGen's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PepGen's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PepGen's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where PepGen's Return-on-Tangible-Asset falls into.


;
;

PepGen Return-on-Tangible-Asset Calculation

PepGen's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-89.981/( (143.052+150.883)/ 2 )
=-89.981/146.9675
=-61.23 %

PepGen's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-120.808/( (150.883+127.393)/ 2 )
=-120.808/139.138
=-86.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


PepGen  (NAS:PEPG) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


PepGen Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of PepGen's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


PepGen Business Description

Industry
Traded in Other Exchanges
N/A
Address
321 Harrison Avenue, 8th Floor, Boston, MA, USA, 02118
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Executives
James G Mcarthur director, officer: President and CEO NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Noel Donnelly officer: Chief Financial Officer PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Michelle L Mellion officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Niels Svenstrup officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jaya Goyal officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
James E Flynn 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Oxford Science Enterprises Plc 10 percent owner 46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT
Laurie Keating director 300 THIRD STREET, CAMBRIDGE MA 02142
Christopher Ashton director PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Management Company, L.p. (series C) 10 percent owner, other: *Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Sonia Bracegirdle officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Mgmt V, L.p. 10 percent owner, other: *Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Private Design Fund V, L.p. 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017